Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN
NCT04743739 · Peking Union Medical College Hospital · PHASE3 · terminated · last registry update 2025-12-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “insufficient patient enrollment” | – | Registry record, Peking Union Medical College Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Also stopped (terminated): Institute of Hematology & Blood Diseases Hospital, China, Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy (NCT06695741)
- 2026-10-19Also stopped (terminated): Boston Children's Hospital, cyclosporine + horse anti-thymocyte globulin (ATG) (NCT05600426)
- 2026-10-16Also stopped (withdrawn): Anjali Sharathkumar, Romiplostim + Immunosuppressive therapy (IST) (NCT07001254)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-06Phase 3 first posted: Peking University First Hospital, Rituximab combined with cyclosporine + rituximab (NCT07861204)
- 2026-10-06Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Sirolimus (NCT02979873)
- 2026-09-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), tocilizumab + Placebo (NCT03644667)
- 2026-09-21Phase 3 first posted: BioRay Pharmaceutical Co., Ltd., Zuberitamab 1000mg + Cyclosporine (NCT07830433)
- 2026-09-18Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Cyclosporin + Mycophenolate mofetil and Dexamethasone (NCT00135811)
- 2026-09-18Phase 3 first posted: Central Hospital, Nancy, France, Eplerenone (NCT07828223)
- 2026-08-19Results posted on the registry: Novaliq GmbH, Cyclosporine ophthalmic solution, 0.1% + Saline solution, 0.6% (NCT06329661)
- 2026-08-10Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag + hATG (NCT03025698)
- 2026-07-31Phase 3 first posted: Hannover Medical School, Everolimus + Tacrolimus or Cyclosporine (NCT07739914)
- 2026-07-21Results posted on the registry: Children's Hospital of Philadelphia, Reduced-Intensity Conditioning (NCT01050855)
- 2026-06-17Phase 3 first posted: Peking Union Medical College Hospital, rhTPO + Cyclosporine (CsA) (NCT07653581)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Luspatercept + cyclosporine (NCT06424639)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Enarodustat + Cyclosporin (CSA) (NCT07522996)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Cyclosporine (CsA) + Thrombopoietin Receptor Agonist (NCT07523009)
- 2026-05-26Results posted on the registry: Eli Lilly and Company, Midazolam + LY3502970 (NCT05573230)
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-20Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Fludarabine + Cyclophosphamide (NCT01962636)
- 2026-05-14Results posted on the registry: Fred Hutchinson Cancer Center, Cyclophosphamide + Cyclosporine (NCT03246906)
- 2026-05-14Also stopped (terminated): Fred Hutchinson Cancer Center, Cyclophosphamide + Cyclosporine (NCT03246906)
- 2026-04-24Also stopped (terminated): European Society for Blood and Marrow Transplantation, G-CSF + Early retreatment with ATG (NCT01163942)
- 2026-04-23Phase 3 first posted: Peking Union Medical College Hospital, Enarodustat + Cyclosporine (CsA) (NCT07548671)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision